Movement Alert｜Sino Biopharmaceutical Falls 3.14% in Regular Trading, Morgan Stanley Cuts Target Price Amid Pharma Sector Selloff

Market Focus06-04 11:24

On June 4, Sino Biopharmaceutical declined 3.14% in regular trading, trading at HK$4.62 per share, with trading volume of HK$186 million.

On the news front, Morgan Stanley recently published a research report cutting the target price for Sino Biopharmaceutical from HK$8.3 to HK$7.8, while maintaining an Overweight rating. The bank incorporated the newly in-licensed bepirovirsen (HBV ASO), which is expected to contribute revenue starting from 2027. Meanwhile, based on management guidance, Morgan Stanley removed the dividend income assumption from Sinovac LS effective from 2026, resulting in EPS forecast cuts of 8%, 7%, and 7% for 2026 through 2028 respectively. The bank also adjusted working capital and capex assumptions to better reflect recent operational trends.

Additionally, the pharmaceutical sector faced broad-based selling pressure, with Luye Pharma down 12.9%, Hengrui Pharma down 4.39%, Simcere Pharma down 2.24%, and Hansoh Pharma down 1.78%, indicating systematic sector weakness exacerbating individual stock declines.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1161390790?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 11:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161390790","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Sino Biopharmaceutical Falls 3.14% in Regular Trading, Morgan Stanley Cuts Target Price Amid Pharma Sector Selloff","media":"Market Focus","content":"<p><p>On June 4, Sino Biopharmaceutical declined 3.14% in regular trading, trading at HK$4.62 per share, with trading volume of HK$186 million.</p><p>On the news front, Morgan Stanley recently published a research report cutting the target price for Sino Biopharmaceutical from HK$8.3 to HK$7.8, while maintaining an Overweight rating. The bank incorporated the newly in-licensed bepirovirsen (HBV ASO), which is expected to contribute revenue starting from 2027. Meanwhile, based on management guidance, Morgan Stanley removed the dividend income assumption from Sinovac LS effective from 2026, resulting in EPS forecast cuts of 8%, 7%, and 7% for 2026 through 2028 respectively. The bank also adjusted working capital and capex assumptions to better reflect recent operational trends.</p><p>Additionally, the pharmaceutical sector faced broad-based selling pressure, with Luye Pharma down 12.9%, Hengrui Pharma down 4.39%, Simcere Pharma down 2.24%, and Hansoh Pharma down 1.78%, indicating systematic sector weakness exacerbating individual stock declines.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Sino Biopharmaceutical Falls 3.14% in Regular Trading, Morgan Stanley Cuts Target Price Amid Pharma Sector Selloff</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Sino Biopharmaceutical Falls 3.14% in Regular Trading, Morgan Stanley Cuts Target Price Amid Pharma Sector Selloff\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-04 11:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 4, Sino Biopharmaceutical declined 3.14% in regular trading, trading at HK$4.62 per share, with trading volume of HK$186 million.</p><p>On the news front, Morgan Stanley recently published a research report cutting the target price for Sino Biopharmaceutical from HK$8.3 to HK$7.8, while maintaining an Overweight rating. The bank incorporated the newly in-licensed bepirovirsen (HBV ASO), which is expected to contribute revenue starting from 2027. Meanwhile, based on management guidance, Morgan Stanley removed the dividend income assumption from Sinovac LS effective from 2026, resulting in EPS forecast cuts of 8%, 7%, and 7% for 2026 through 2028 respectively. The bank also adjusted working capital and capex assumptions to better reflect recent operational trends.</p><p>Additionally, the pharmaceutical sector faced broad-based selling pressure, with Luye Pharma down 12.9%, Hengrui Pharma down 4.39%, Simcere Pharma down 2.24%, and Hansoh Pharma down 1.78%, indicating systematic sector weakness exacerbating individual stock declines.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1161390790","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161390790","pubTimestamp":1780543484,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 4, Sino Biopharmaceutical declined 3.14% in regular trading, trading at HK$4.62 per share, with trading volume of HK$186 million.On the news front, Morgan Stanley recently published a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"动向提示|中国生物制药常规交易跌3.14%医药板块抛售大摩下调目标价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"On June 4, Sino Biopharmaceutical declined 3.14% in regular trading, trading at HK$4.62 per share, with trading volume of HK$186 million.On the news front, Morgan Stanley recently published a research report cutting the target price for Sino Biopharmaceutical from HK$8.3 to HK$7.8, while maintaining an Overweight rating. The bank incorporated the newly in-licensed bepirovirsen (HBV ASO), which is expected to contribute revenue starting from 2027. Meanwhile, based on management guidance, Morgan Stanley removed the dividend income assumption from Sinovac LS effective from 2026, resulting in EPS forecast cuts of 8%, 7%, and 7% for 2026 through 2028 respectively. The bank also adjusted working capital and capex assumptions to better reflect recent operational trends.Additionally, the pharmaceutical sector faced broad-based selling pressure, with Luye Pharma down 12.9%, Hengrui Pharma down 4.39%, Simcere Pharma down 2.24%, and Hansoh Pharma down 1.78%, indicating systematic sector weakness exacerbating individual stock declines.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1161390790","isCrawlerRequest":true}